Lamivudine (Mylan Pharmaceuticals Inc.)
Welcome to the PulseAid listing for the Lamivudine drug offered from Mylan Pharmaceuticals Inc.. This Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Mylan Pharmaceuticals Inc. |
NON-PROPRIETARY NAME: | lamivudine |
SUBSTANCE NAME: | LAMIVUDINE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET, FILM COATED |
MARKETING CATEGORY NAME: | ANDA |
START MARKETING DATE: | 2015-01-09 |
END MARKETING DATE: | 0000-00-00 |
Lamivudine HUMAN PRESCRIPTION DRUG Details:
Item Description | Lamivudine from Mylan Pharmaceuticals Inc. |
LABELER NAME: | Mylan Pharmaceuticals Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 100(mg/1) |
START MARKETING DATE: | 2015-01-09 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0378-5168_4c90067f-8f41-443a-8afc-ff461d72e2f6 |
PRODUCT NDC: | 0378-5168 |
APPLICATION NUMBER: | ANDA204002 |
Other LAMIVUDINE Pharmaceutical Manufacturers / Labelers: